Key result
Propafenone administration in patients with symptomatic ventricular arrhythmias did not demonstrate clinically significant beta-blocking effects on heart rate or blood pressure at rest or during exercise.
Why the study?
Does propafenone exert clinically significant beta-blocking effects on electrocardiographic variables in patients with symptomatic ventricular arrhythmias?
Population
42 patients with symptomatic ventricular arrhythmias (31 underwent exercise testing)
Comparison
Propafenone vs Baseline (before propafenone administration)
Design
Cohort
Authors
Loading...
Propafenone lacks clinically significant beta-blocking effects in symptomatic VA; supports class Ic profile but leaves ECG impact open for RCTs.
Observational (n=42)
Does propafenone exert clinically significant beta-blocking effects on electrocardiographic variables in patients with symptomatic ventricular arrhythmias?
Propafenone demonstrates expected class 1c antiarrhythmic effects but lacks clinically significant beta-blocking effects at rest or during exercise.
Cheriex et al. (1987) conducted an observational in Symptomatic ventricular arrhythmias (n=42). Propafenone vs. Baseline (before propafenone) was evaluated on Electrocardiographic variables at rest and during exercise. Propafenone administration in patients with symptomatic ventricular arrhythmias did not demonstrate clinically significant beta-blocking effects on heart rate or blood pressure at rest or during exercise.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: